Page last updated: 2024-12-11
tezacitabine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
tezacitabine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 6435808 |
| CHEMBL ID | 2105467 |
| SCHEMBL ID | 18724 |
| SCHEMBL ID | 18725 |
| MeSH ID | M0383847 |
Synonyms (39)
| Synonym |
|---|
| mdl-101731 |
| kw-2331 |
| tezacitabine |
| mdl 101731 |
| fmdc cpd |
| 2'-deoxy-2'-(fluoromethylene)cytidine |
| cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2e)- |
| mdl 101,731 |
| 4-amino-1-[(2r,3e,4s,5r)-3-(fluoromethylidene)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one |
| (e)-2'-deoxy-2'-(fluoromethylene)cytidine |
| tezacitabine, anhydrous |
| 130306-02-4 |
| unii-7607y95n9s |
| tezacitabine [inn] |
| tezacitabine, anhydrous [inn] |
| 7607y95n9s , |
| fmd-c |
| CHEMBL2105467 |
| cytidine, 2'-deoxy-2'-(fluoromethylene)- |
| 171233-40-2 |
| (2'e)-2'-deoxy-2'-(fluoromethylene)cytidine |
| cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2'e)- |
| tezacitabine [who-dd] |
| 2'-deoxy-2'-((e)-fluoromethylene)cytidine |
| tezacitabine anhydrous |
| GFFXZLZWLOBBLO-ASKVSEFXSA-N |
| SCHEMBL18724 |
| SCHEMBL18725 |
| (e)-2'-deoxy-2'-(fluoromethylene) cytidine |
| DTXSID10156446 |
| 4-amino-1-((2r,4s,5r,e)-3-(fluoromethylene)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1h)-one |
| Q383775 |
| mfcd00893181 |
| DB06433 |
| fmdc; kw 2331; mdl 101731 |
| 4-amino-1-((2r,4s,5r)-3-(fluoromethylene)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1h)-one |
| MS-23621 |
| CS-0024626 |
| HY-106014 |
Research Excerpts
Overview
Tezacitabine (FMdC) is a new cytostatic/cytotoxic agent widely investigated in clinical trials and on the cellular level. It is a nucleoside analogue characterized by a dual mechanism of action.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Tezacitabine (FMdC) is a new cytostatic/cytotoxic agent widely investigated in clinical trials and on the cellular level. " | ( Tezacitabine blocks tumor cells in G1 and S phases of the cell cycle and induces apoptotic cell death. Grieb, P; Koronkiewicz, M; Skierski, JS, ) | 3.02 |
| "Tezacitabine is a nucleoside analogue characterized by a dual mechanism of action. " | ( Tezacitabine enhances the DNA-directed effects of fluoropyrimidines in human colon cancer cells and tumor xenografts. Aardalen, K; Doyle, L; Hibner, B; Jekic-McMullen, D; Moler, E; Rendahl, K; Salangsang, F; Shao, Y; Taverna, P, 2007) | 3.23 |
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " After 24 h incubation tezacitabine was equally or less toxic compared to cladribine." | ( Cytotoxic effects of cladribine and tezacitabine toward HL-60. Grieb, P; Skierski, JS; Stachnik, K, 2005) | 0.91 |
Compound-Compound Interactions
| Excerpt | Reference | Relevance |
|---|---|---|
| "Tezacitabine at a dose of 200 mg/m(2) in combination with CI 5-FU at a dose of 200 mg/m(2) per day was relatively well tolerated and had clinical activity in patients with advanced solid tumors, particularly in patients with esophageal and other gastrointestinal carcinomas." | ( Phase I dose-escalation study of tezacitabine in combination with 5-fluorouracil in patients with advanced solid tumors. Bendell, JC; Clark, JW; Eder, JP; Fidias, P; Lynch, TJ; Ryan, DP; Seiden, MV, 2005) | 2.05 |
Dosage Studied
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (25)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (60.00) | 18.2507 |
| 2000's | 10 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 18.24
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (18.24) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 6 (19.35%) | 5.53% |
| Reviews | 4 (12.90%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 21 (67.74%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Clinical Trials (3)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00051688] | Phase 2 | 0 participants | Interventional | 2003-06-30 | Terminated | ||
| [NCT00054873] | Phase 2 | 0 participants | Interventional | 2003-11-30 | Completed | ||
| Phase I Study of Continuous Infusion Schedule of (E)-2'-Deoxy-2'-(Fluoromethylene) Cytidine (Tezacitabine, FMdC) in Hematologic Malignancies [NCT00061620] | Phase 1 | 19 participants (Actual) | Interventional | 2001-09-06 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||